On Tuesday, Shares of Freeport-McMoRan Inc. (NYSE:FCX), lost -3.92% to $18.62.
Freeport-McMoRan Inc., declared a cash dividend of $0.1605 per share payable on August 3, 2015 to holders of record as of July 15, 2015 for its common stock.
The August 2015 common stock dividend comprises of $0.05 per share for FCX’s regular quarterly dividend and $0.1105 per share as a special dividend related to the formerly declared settlement of the stockholder derivative litigation approved by the Delaware Court of Chancery in April 2015.
Freeport-McMoRan Inc., a natural resource company, engages in the acquisition of mineral assets, and oil and natural gas resources. It primarily explores for copper, gold, molybdenum, cobalt, silver, and other metals, in addition to oil and gas.
Shares of Baxter International Inc. (NYSE:BAX), declined -1.02% to $37.99, during its last trading session.
PharmaEngine, Inc. (4162.TWO) declared that (1) its license partner, Merrimack Pharmaceuticals, Inc. (MACK), has received the notification from the US Food and Drug Administration (FDA) for the acceptance and the grant of the priority review designation for their New Drug Application (NDA); and (2) its sublicense partner, Baxalta Incorporated, a wholly owned partner of Baxter International Inc. (BAX) has received the acceptance of Market Authorization Application (MAA) from the European Medicines Agency (EMA), of MM-398 (irinotecan liposome injection, also known as “nal-IRI,”) in the treatment of patients with metastatic adenocarcinoma of the pancreas who have been formerly treated with gemcitabine-based therapy.
A priority review designation is granted to medicines that the US FDA determines, have the potential to provide noteworthy improvements in the safety or effectiveness. The aim is for the FDA to take action on the marketing application within 6 months of receipt (contrast with 10 months under standard review) of the NDA submission. .
“We are very excited to know that the two major regulatory agencies, the US FDA and the EMA, have accepted the NDA and MAA applications in their respective jurisdictions for MM-398,” said C. Grace Yeh, Ph.D., President and CEO of PharmaEngine. “We believe that MM-398 will provide an option to the limited armamentarium for the treatment of the metastatic pancreatic cancer in the foreseeable future.”
Baxter International Inc., develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.
Finally, Ensco plc (NYSE:ESV), ended its last trade with 0.23% gain, and closed at $22.27.
Ensco plc, will hold its second quarter 2015 earnings conference call at 10:00 a.m. CDT (11:00 a.m. EDT and 4:00 p.m. London) on Thursday, 30 July 2015. The earnings release will be issued before the New York Stock Exchange opens that morning. The conference call will be webcast live at www.enscoplc.com. Interested parties also may listen to the call by dialing 1-855-239-3215 within the United States, or +1-412-542-4130 from outside the U.S., and asking for the Ensco conference call. It is recommended that participants call 20 minutes before the planned start time.
Ensco plc provides offshore contract drilling services to the oil and gas industry worldwide. The company operates through three segments: Floaters, Jackups, and Other. The company owns and operates offshore drilling rig fleet of 70 rigs, counting 10 drillships, 13 semisubmersible rigs, 5 moored semisubmersible rigs, and 42 jackup rigs located in North and South America, the Middle East and Africa, the Asia Pacific rim, Europe and the Mediterranean, and Brazil.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
